{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:14:56Z","timestamp":1758190496977,"version":"3.44.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bladder cancer (BC) is a common malignancy characterized by high recurrence and poor prognosis. HOXB7, a member of the HOX gene family, is aberrantly expressed in various tumors, but its role in BC remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HOXB7 expression in BC was analyzed using public databases (GEPIA, UALCAN) and validated by immunohistochemistry on a tissue microarray of 36 BC patients. <jats:italic>In vitro<\/jats:italic> experiments using BC cell lines (5637 and T24) were conducted to investigate the effects of HOXB7 knockdown or overexpression on cell proliferation, apoptosis, migration, invasion, and epithelial\u2013mesenchymal transition (EMT). Western blotting and rescue assays with ERK pathway modulators (Ro67\u20137476 and PD98059) were performed to assess the involvement of the H-Ras\/Raf-1\/MEK\/ERK signaling cascade. Xenograft mouse models were employed to evaluate tumorigenicity <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HOXB7 was significantly upregulated in BC tissues and cell lines, correlating with advanced tumor stage and poor overall survival. HOXB7 silencing inhibited BC cell proliferation, migration, invasion, and EMT, while promoting apoptosis. Conversely, HOXB7 overexpression produced the opposite effects. Mechanistically, HOXB7 activated the H-Ras\/Raf-1\/MEK\/ERK pathway, as indicated by increased phosphorylation of MEK and ERK. These effects were reversed by pharmacological inhibition or activation of ERK signaling. <jats:italic>In vivo<\/jats:italic>, HOXB7 knockdown suppressed tumor growth and ERK pathway activation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides the first comprehensive experimental evidence that HOXB7 drives BC progression via activation of the H-Ras\/Raf-1\/MEK\/ERK pathway. These findings highlight HOXB7 as a potential prognostic biomarker and therapeutic target in BC. Furthermore, our results lay the foundation for future investigations into the broader molecular and immunological networks modulated by HOXB7 in BC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1645803","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:38:10Z","timestamp":1758087490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["HOXB7 drives bladder cancer progression via H-Ras\/ERK signaling: a potential therapeutic target and prognostic biomarker"],"prefix":"10.3389","volume":"15","author":[{"given":"Xulong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quliang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.04.015","article-title":"Prognostic performance and reproducibility of the 1973 and 2004\/2016 world health organization grading classification systems in non-muscle-invasive bladder cancer: A European association of urology non-muscle invasive bladder cancer guidelines panel systematic review","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.031","article-title":"circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p\/TGFbetaR1\/VEGF-D signaling","volume":"29","author":"Zhu","year":"2021","journal-title":"Mol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.12.006","article-title":"Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy","volume":"35","author":"Moschini","year":"2017","journal-title":"Urol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2018.05.49","article-title":"Emerging biomarkers and targeted therapies in urothelial carcinoma","volume":"6","author":"Mendiratta","year":"2018","journal-title":"Ann Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.3390\/cancers12113299","article-title":"HOX genes family and cancer: A novel role for homeobox B9 in the resistance to anti-angiogenic therapies","volume":"12","author":"Contarelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/092986711797535182","article-title":"The HOX genes network in uro-genital cancers: mechanisms and potential therapeutic implications","volume":"18","author":"Cantile","year":"2011","journal-title":"Curr Med Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27926","article-title":"The relationship between homeobox B7 expression and the clinical characteristics of patient with prostate cancer","volume":"120","author":"Song","year":"2019","journal-title":"J Cell Biochem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108822","DOI":"10.1016\/j.biopha.2019.108822","article-title":"MicroRNA-384 is lowly expressed in human prostate cancer cells and has anti-tumor functions by acting on HOXB7","volume":"114","author":"Hong","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.10.029","article-title":"Inhibition of Ras\/Raf\/MEK\/ERK pathway signaling by a stress-induced phospho-regulatory circuit","volume":"64","author":"Ritt","year":"2016","journal-title":"Mol Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.66","article-title":"Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy","volume":"25","author":"Steelman","year":"2011","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41419-023-05970-2","article-title":"PLAGL2 promotes bladder cancer progression via RACGAP1\/RhoA GTPase\/YAP1 signaling","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac006","article-title":"NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer","volume":"43","author":"Qian","year":"2022","journal-title":"Carcinogenesis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-017-0559-4","article-title":"HOXB7 accelerates the Malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition","volume":"36","author":"Huan","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.04102.x","article-title":"HOXB7 expression is a prognostic factor for oral squamous cell carcinoma","volume":"60","author":"Bitu","year":"2012","journal-title":"Histopathology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2533","article-title":"HOXB7 as a prognostic factor and mediator of colorectal cancer progression","volume":"17","author":"Liao","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018859108","article-title":"The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway","volume":"109","author":"Jin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-018-0150-4","article-title":"Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis","volume":"99","author":"Dai","year":"2019","journal-title":"Lab Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13287-019-1200-6","article-title":"Impact of HOXB7 overexpression on human adipose-derived mesenchymal progenitors","volume":"10","author":"Foppiani","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S198115","article-title":"Homeobox B7 accelerates the cancer progression of gastric carcinoma cells by promoting epithelial-mesenchymal transition (EMT) and activating Src-FAK pathway","volume":"12","author":"Wu","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4470","article-title":"HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3100","article-title":"HOXB7 promotes Malignant progression by activating the TGFbeta signaling pathway","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/cells10102509","article-title":"ERK: A double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer","volume":"10","author":"Sugiura","year":"2021","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17004","article-title":"HOXB7 promotes tumor progression via bFGF-induced activation of MAPK\/ERK pathway and indicated poor prognosis in hepatocellular carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.772780","article-title":"The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells","volume":"292","author":"Tsuboi","year":"2017","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/15216540600957438","article-title":"ERK1\/2 MAP kinases in cell survival and apoptosis","volume":"58","author":"Lu","year":"2006","journal-title":"IUBMB Life"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","article-title":"ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence","volume":"277","author":"Cagnol","year":"2010","journal-title":"FEBS J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2926","article-title":"Hoxb7 inhibits transgenic HER-2\/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis","volume":"68","author":"Chen","year":"2008","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4283","article-title":"A role for the HOXB7 homeodomain protein in DNA repair","volume":"67","author":"Rubin","year":"2007","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13142","article-title":"HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair","volume":"11","author":"Zhou","year":"2020","journal-title":"Thorac Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-1112","article-title":"ERK inhibition improves anti-PD-L1 immune checkpoint blockade in preclinical pancreatic ductal adenocarcinoma","volume":"20","author":"Henry","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/ijms20102505","article-title":"ERK is a pivotal player of chemo-immune-resistance in cancer","volume":"20","author":"Salaroglio","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1645803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:38:11Z","timestamp":1758087491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1645803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":35,"alternative-id":["10.3389\/fonc.2025.1645803"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1645803","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1645803"}}